Original Paper

Medical Oncology

, Volume 28, Supplement 1, pp 570-576

First online:

Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases

  • Liang-Ping XiaAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Hui-Juan QiuAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Xu-Xian ChenAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Pi-Li HuAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Gui-Fang GuoAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Fang WangAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Fei-Fei ZhouAffiliated withTumor Center, The Foshan First People’s Hospital
  • , Wen-Zhuo HeAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
  • , Bei ZhangAffiliated withState Key Laboratory of Oncology in South ChinaVIP Region, Sun Yat-sen University Cancer Center
    • , Li ZhangAffiliated withState Key Laboratory of Oncology in South ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Cetuximab combined with chemotherapy has been used to treat Non-small cell lung cancer (NSCLC) in recent years, however, the data from China was rare. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the first line setting. From October 1st 2006 to Jun 30th 2010, twelve NSCLC patients were treated with cetuximab combined standard chemotherapy as first line setting in Sun Yat-sen University Cancer Center entered the study and the short-term efficacy and safety were analyzed. A total of 132 cycles of cetuximab treatment, with a median of nine cycles in the whole group were administered. The ORR was 41.7% (5/12), DCR was 83.3% (10/12), median TTP was 5.5 months (2–23), and median OS was 9 months (2–48) in the whole group. There were 75% (9/12) patients occurred acne-like rash within first 3 weeks, their ORR was 55.6% (5/9), DCR was 100% (9/9), however, ORR and DCR in patients who didn’t occurred acne-like rash within first 3 weeks were 0 and 33.3% (1/3), the difference ORR between two group was insignificant (P = 0.091), however, DCR was significant different (P = 0.007). There no treatment-associated death and no cetuximab-associated discontinuation. The incidence of acne-like rash was 83.3% (10/12) and 75% (9/12) occurred within first 3 weeks, there were eight patients suffered side effects associated with chemotherapy. So we can draw a conclusion that the short-term outcome of cetuximab application in first line setting for patients with NSCLC were promising since the higher ORR and DCR, especially those occurred acne-like rash within the first 3 weeks, and the addition of cetuximab in this population was safe.

Keywords

Cetuximab Non-small cell lung cancer Efficacy Safety First line Chemotherapy